Courier Capital LLC Purchases New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Courier Capital LLC acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the fourth quarter, Holdings Channel.com reports. The firm acquired 56,438 shares of the biopharmaceutical company’s stock, valued at approximately $482,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in OCUL. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in Ocular Therapeutix by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company’s stock worth $3,860,000 after buying an additional 1,168 shares in the last quarter. Amalgamated Bank increased its stake in Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,481 shares in the last quarter. HighVista Strategies LLC raised its holdings in shares of Ocular Therapeutix by 5.1% during the third quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company’s stock valued at $566,000 after acquiring an additional 3,168 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Ocular Therapeutix by 36.9% in the second quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 4,695 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on OCUL shares. Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Insiders Place Their Bets

In other news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by insiders.

Ocular Therapeutix Trading Down 1.1 %

Shares of OCUL stock opened at $8.12 on Tuesday. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a twelve month low of $3.76 and a twelve month high of $11.77. The company’s 50-day moving average price is $9.22 and its 200-day moving average price is $8.95. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -6.15 and a beta of 1.23.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.